UCD

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Retrieved on: 
Thursday, March 28, 2024
Narcolepsy, Exercise, Somnolence, New Drug Application, Patient, Visual analogue scale, Sale, NDA, G&A, Arimoclomol, Nature, IND, Bank statement, Microsoft Access, Investment, Therapy, Priority review, Corporation, Audit committee, Research, Niemann–Pick disease, Medical science liaison, Sleep disorder, Brain, Trial of the century, Safety, Interim, Food, Sleep, QuickStart, Disease, FY, Acquisition, Emetine, UCD, COL3A1, Celiprolol, Syndrome, FDA, Marketing, Conference call, Conference, EAP, SDX, NPC, Epworth Sleepiness Scale, Idiopathic hypersomnia, Physician, PDUFA, Pharmaceutical industry

CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023. 

Key Points: 
  • ET
    CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023.
  • “We made solid progress on our key priorities in 2023,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
  • Overview of Q4 2023 and FY 2023 Financial Results:
    Net revenue for Q4 2023 was $13.2 million, compared to prior year Q4 net revenue of $2.2 million.
  • ET, to discuss its corporate and financial results for Q4 and FY 2023.

CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders

Retrieved on: 
Thursday, March 21, 2024
Disability, Gene, Enzyme, Seizure, Patient, DSM-IV codes, RNA, Messenger, Protein, Trial of the century, CPS1, UCD, Clinical trial, Therapy, Safety, Pharmacokinetics, Ammonia, Brain damage, Disorder, Blood, Pharmaceutical industry

“Most importantly, the clinical development of CMP-CPS-001 is a step toward potentially bringing a new, disease-modifying treatment to individuals living with UCDs.

Key Points: 
  • “Most importantly, the clinical development of CMP-CPS-001 is a step toward potentially bringing a new, disease-modifying treatment to individuals living with UCDs.
  • People with urea cycle disorders accumulate excessive ammonia in their blood, which may cause irreversible brain damage, disability, and seizures, and may be fatal.
  • CMP-CPS-001 targets carbamoyl phosphate synthetase 1 (CPS1), a key enzyme that catalyzes the first step of the urea cycle.
  • For more information about the Phase 1 clinical study of CMP-CPS-001, please visit clinicaltrials.gov ( NCT06247670 ).

UCD Smurfit School appoints David McCourt as Adjunct Professor to support leadership in Artificial Intelligence

Retrieved on: 
Wednesday, March 20, 2024
Marriage, United, Public policy, United Nations, Policy, Child, Entrepreneurship, AI, Private sector, Student, Leg, UCD, McCourt, System, Economist, Digital technology, Telecommunications, Artificial intelligence, National broadband plan, School, Management

DUBLIN, March 20, 2024 /PRNewswire/ -- UCD Michael Smurfit Graduate Business School has announced that technology, media, and telecommunications entrepreneur David McCourt has been appointed as an Adjunct Full Professor to support the School's national and global leadership ambitions in Artificial Intelligence.

Key Points: 
  • DUBLIN, March 20, 2024 /PRNewswire/ -- UCD Michael Smurfit Graduate Business School has announced that technology, media, and telecommunications entrepreneur David McCourt has been appointed as an Adjunct Full Professor to support the School's national and global leadership ambitions in Artificial Intelligence.
  • As founder and CEO of worldwide investment firm Granahan McCourt Capital and the Chairman of National Broadband Ireland, McCourt is described by The Economist as possessing "impeccable credentials as a telecom revolutionary".
  • As Adjunct Professor, McCourt will deliver a number of lectures on AI, technology, entrepreneurship, and leadership to students across all levels and will also provide guidance in programme development, thought leadership and industry engagement.
  • Commenting on his appointment, David McCourt added, "It is an honor to join UCD as an Adjunct Professor and I am especially pleased to contribute to the School's vision for AI.

Pheburane® (sodium phenylbutyrate) is now on the Medicaid Preferred Drug List in 10 states

Retrieved on: 
Tuesday, January 23, 2024
Patient, Government, Medicaid, Ammonia, Digestion, Health, Standard of care, Pharmacy, DSM-IV codes, DPG, Blood, UCD, Appetite, Pharmaceutical industry

Pheburane® is the safe, effective and palatable adjunctive therapy to the standard of care, which includes dietary management, for the treatment of certain UCDs.

Key Points: 
  • Pheburane® is the safe, effective and palatable adjunctive therapy to the standard of care, which includes dietary management, for the treatment of certain UCDs.
  • With the continued favorable commercial and Medicaid coverage updates, Pheburane® is reaching more patients all over the USA while being recognized as a first-line therapy by health authorities in key states.
  • UCDs are rare, chronic, genetic conditions that can be fatal if left untreated, and can impact children from the time of birth.
  • UNIK Support offers specialized services including a copay savings program, patient care liaison services, mail order pharmacy and other support services.

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

Retrieved on: 
Thursday, December 7, 2023
Liver, UDCA, Chapter Two, Woman, FDA, MAA, Fatigue, Nausea, Primary biliary cholangitis, Inflammation, ADR, Patent, Liver disease, Diagnosis, AMF, CHMP, Ascending cholangitis, UCD, Business, ACLF, PDUFA, Itch, Risk, New Drug Application, OA, Common, EASL, MASH, Liver failure, Safety, Ammonia, Elafibranor, Therapy, Epidemiology, History, Patient, Cholangiocarcinoma, Food, Health care, EMA, Ursodeoxycholic acid, MHRA, Cirrhosis, Medicine, NTZ, EVP, Cholestasis, NASH, Research, Diarrhea, Bile, NDA, PBC, Abdominal pain, Clinical trial, European Medicines Agency, IPN, PPAR, P10, CCA, Fibrosis, Pharmaceutical industry

An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade.

Key Points: 
  • An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade.
  • The trial enrolled 161 patients who were randomized 2:1 to receive either elafibranor 80mg once daily or placebo.
  • ELATIVE also investigated the effect of treatment with elafibranor on pruritus (severe itch), a significant symptom burden amongst people living with PBC.
  • Findings from the secondary endpoint using the PBC Worst Itch NRS score, showed a reduction in pruritis for elafibranor, which was not statistically significant.

Taoglas Shoots for the Stars in Ireland's First Satellite

Retrieved on: 
Monday, December 4, 2023
Aerospace, IOT (Internet of Things), Manufacturing, Satellite, Technology, CubeSat, European Space Agency, Internet of things, Engineering, RF, GPS, Shock, University College Dublin, Space research, Student, Education, Multimedia, GNSS, Orbit, SpaceX, SpaceX launch vehicles, UCD, Communications satellite, Surveying

Taoglas' GPS/GALILEO patch antenna was chosen for its lightweight and low-volume characteristics while ensuring high gain and wide bandwidth.

Key Points: 
  • Taoglas' GPS/GALILEO patch antenna was chosen for its lightweight and low-volume characteristics while ensuring high gain and wide bandwidth.
  • "We are immensely proud that Ireland's first satellite, EIRSAT-1, will have an Irish satellite antenna and cable solution on board.
  • Taoglas provided the ideal solution with their direct solder mount GNSS antenna, demonstrating the innovation and precision necessary for this pioneering mission."
  • You can watch Taoglas’ video about their involvement in the EIRSAT-1 mission here: https://youtu.be/fr3ZtYtXT0g

Pheburane® (sodium phenylbutyrate) coverage to reach ~80% of commercially insured US patients by January 1st, 2024

Retrieved on: 
Thursday, October 26, 2023
Government, Ammonia, History, Courage, Digestion, OTC, UCD, Health, DSM-IV codes, UCD School of Medicine, CPS, Disease, Pharmacy, Medicaid, Sodium phenylbutyrate, Patient, Government of Canada, Appetite, Pharmaceutical industry

Pheburane® is not indicated for the treatment of acute hyperammonemia which can be life-threatening and requires emergency medical treatment.

Key Points: 
  • Pheburane® is not indicated for the treatment of acute hyperammonemia which can be life-threatening and requires emergency medical treatment.
  • UCDs are rare, chronic, genetic conditions that can be fatal if left untreated, and can impact children from the time of birth.
  • It does not require any mixing or oral syringes and there is no weight restriction for patients.
  • UNIK Support offers specialized services including a copay savings program, patient care liaison services, mail order pharmacy and other support services.

InScribe Expands International Access to Its Transformative Community to Enhance Learner Support and Well-Being

Retrieved on: 
Thursday, October 5, 2023
European, Republic of Ireland, Student, United Kingdom, GDPR, UCD, Entrepreneurship, Education, Ireland, University College Dublin, Michael Smurfit Graduate Business School, Educational technology, Privacy, EU, Compulsory figures, Tutoring

DENVER, Oct. 5, 2023 /PRNewswire-PRWeb/ -- InScribe, a leading provider of digital communities for higher education, has announced that it has extended access to its innovative student engagement platform for institutions across the European Union and the United Kingdom. The EdTech company is dedicated to helping institutions improve their approach to student support while also focusing on their commitment to fostering students' sense of belonging and well-being.

Key Points: 
  • "With these proven results, we're excited to expand our reach internationally to support a broader range of post-secondary learners," said Katy Kappler, Co-Founder and CEO of InScribe.
  • InScribe is a leading platform for virtual student communities across the United States.
  • With these proven results, we're excited to expand our reach internationally to support a broader range of post-secondary learners," said Katy Kappler, Co-Founder and CEO of InScribe.
  • University College Dublin, located in the Republic of Ireland is among the initial wave of EU-based institutions partnering with InScribe.

EXL expands operations into Dublin and establishes a headquarters for international business

Retrieved on: 
Monday, October 2, 2023
Heart, Education, EXL, UCD, University College Dublin, Intelligence, Research, IDA Ireland, Machine learning, Medical device, Sales, AI

NEW YORK and DUBLIN, Ireland, Oct. 02, 2023 (GLOBE NEWSWIRE) -- EXL, a leading data analytics and digital operations and solutions company, announced it will establish a headquarters for international business in Dublin.

Key Points: 
  • NEW YORK and DUBLIN, Ireland, Oct. 02, 2023 (GLOBE NEWSWIRE) -- EXL, a leading data analytics and digital operations and solutions company, announced it will establish a headquarters for international business in Dublin.
  • EXL plans to hire up to 200 artificial intelligence, data engineers and other technology positions in Dublin over the next three years.
  • As part of its expansion into Ireland, EXL announced a new collaboration with University College Dublin (UCD), one of Europe’s leading research-intensive universities.
  • EXL will also work with the Center for Applied AI or CeADAR, Europe’s Digital Innovation Hub for AI in Ireland.

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

Retrieved on: 
Thursday, August 31, 2023
LLP, Business development, Relief Therapeutics, Contingent value rights, NOL, William Blair & Company, UCD, Business, Pillsbury Winthrop Shaw Pittman, Emetine, UCD GAA, Acquisition, VWAP, Patient, Niemann–Pick disease, Physician, CVR College of Engineering, Webcast, ACER, NPC, Rare, FDA, Therapy, Pharmaceutical industry, Security (finance), Financial adviser, Zebra, Acer

Zevra has also purchased Acer’s secured debt at a discount from Nantahala Capital (Nantahala) through a series of transactions in capital efficient structure.

Key Points: 
  • Zevra has also purchased Acer’s secured debt at a discount from Nantahala Capital (Nantahala) through a series of transactions in capital efficient structure.
  • In addition, Zevra has agreed to provide Acer with a bridge loan facility for up to $16.5 million, subject to certain terms and conditions.
  • The merger is expected to expand Zevra's rare disease portfolio, as well as increase and diversify its revenues with the addition of a U.S. commercial asset, OLPRUVA, indicated for the treatment of UCDs.
  • Pillsbury Winthrop Shaw Pittman LLP served as legal advisor to Acer, and William Blair & Company, LLC served as exclusive financial advisor to Acer.